Ostatní
Návod 
Lantheus Holdings, Inc.
LNTH
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
3.5B
Obrat
2B
Zisk
0B
Aktiva
2B
Dluh
1B
ROE
15%
ROA
7%
PE
22
PS
3
Cena 1R
47-111
⌀ Cena
69.05
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
26-02-2026
Poslední dividenda
Profil
Společnost Lantheus Holdings, Inc. vyvíjí, vyrábí a komercializuje diagnostické a terapeutické přípravky, které pomáhají klinickým lékařům v diagnostice a léčbě srdečních, rakovinných a dalších onemocnění po celém světě. Poskytuje DEFINITY, mikrobublinový ultrazvukový zesilovač používaný při ultrazvukových vyšetřeních srdce; TechneLite, technologický generátor pro nukleární medicínu; Xenon-133 k vyhodnocení plicní funkce; Neurolit k identifikaci oblasti v mozku, kde byl průtok krve zablokován nebo snížen v důsledku mrtvice; Kardiolit, injekční zobrazovací prostředek značený Tc-99m; Thallium-201 k detekci kardiovaskulárních onemocnění; a Gallium-67 k detekci různých infekcí a rakovinových nádorů. Společnost také nabízí přípravek AZEDRA, což je radioterapeutické léčivo pro dospělé a dětské pacienty; Automatizovaný index skenování kostí, který vypočítává nálož onemocnění rakoviny prostaty pomocí kvantifikace hotspotů na skenování kostí; a Cobalt (Co 57), nefarmaceutický radiochemický; RELISTOR pro zácpu vyvolanou opioidy; a PYLARIFY pro vizualizaci lymfatických uzlin, kostních a měkkých tkáňových metastáz za účelem stanovení přítomnosti nebo nepřítomnosti recidivujícího a/nebo metastazujícího karcinomu prostaty. Vyvíjí také flurpiridaz F 18 pro hodnocení průtoku krve do srdce; 1095, což je malá molekula značená jodem 131, zaměřená na PSMA; LMI 1195 pro nádory neuroblastomu u dětí a dospělých; PYLARIFY AI, software pro zdravotnické prostředky na bázi AI pro provádění standardizovaného kvantitativního hodnocení PSMA PET/CT snímků u karcinomu prostaty; a leronlimab, zkoumaná humanizovaná monoklonální protilátka. Podnik obsluhuje rozhlasové lékárny, distributory, integrované distribuční sítě, nemocnice, kliniky a skupinové praktiky. Má strategická partnerství s NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; a POINT Biopharma US Inc. Společnost byla založena v roce 1956 a sídlí v North Billerica, Massachusetts.
Sektor
Healthcare
Odvětví
Drug Manufacturers - Specialty & Generic
Počet zaměstnanců
808
Založení
2015-06-25
Podobné společnosti
$ 22.42
- $ 0.15
$ 11.51
+ $ 0.14
$ 14.45
- $ 0.08
$ 45.02
- $ 1.00
$ 166.74
- $ 1.48
$ 15.08
+ $ 0.13
$ 6.60
- $ 0.05
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 1,541.6 | 1,541.6 | 1,533.9 | 1,296.4 | 935.1 | 425.2 | 339.4 | 347.3 | 343.4 | 331.4 | 301.9 | 293.5 | 301.6 | 283.7 | 288.1 | 356.3 | |
| Cost of Revenues | 599.7 | 599.7 | 545.6 | 586.9 | 353.4 | 237.5 | 200.6 | 172.5 | 168.5 | 169.2 | 164.1 | 157.9 | 176.1 | 206.3 | 212.9 | 261.1 | |
| Gross Profit | 942.0 | 942.0 | 988.3 | 709.5 | 581.7 | 187.7 | 138.8 | 174.8 | 174.9 | 162.1 | 137.8 | 135.5 | 125.5 | 77.4 | 75.2 | 95.2 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 406.8 | 384.0 | 378.0 | 372.8 | 391.1 | 378.7 | 394.1 | 370.0 | 354.0 | 319.9 | |
| Cost of Revenues | 165.9 | 161.6 | 137.0 | 135.1 | 142.6 | 136.6 | 138.3 | 118.2 | 124.1 | 120.0 | |
| Gross Profit | 240.9 | 222.4 | 241.0 | 237.7 | 248.5 | 242.1 | 255.8 | 251.8 | 229.9 | 200.0 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 77.7 | 311.7 | 45.0 | 32.8 | 20.0 | 17.1 | 18.1 | 12.2 | 14.4 | 13.7 | 30.5 | 40.6 | 40.9 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 267.2 | 233.8 | 218.8 | 110.2 | 103.1 | 93.3 | 92.2 | 75.4 | 78.6 | 72.4 | 68.3 | 70.0 | 71.6 | |
| Depreciation & Amortization | 70.1 | 70.1 | 64.6 | 60.0 | 47.9 | -7.4 | 2.2 | 13.4 | 13.9 | 19.2 | 18.3 | 19.7 | 18.3 | 25.2 | 27.4 | 32.8 | |
| Total Operating Expenses | 631.1 | 631.1 | 531.3 | 344.9 | 545.5 | 263.8 | 143.0 | 123.2 | 110.4 | 110.3 | 87.6 | 93.0 | 86.1 | 98.7 | 110.6 | 112.5 | |
| Operating Income | 310.8 | 310.8 | 457.0 | 364.6 | -13.4 | -76.1 | -4.2 | 32.1 | 64.5 | 51.9 | 56.6 | 42.5 | 39.4 | -18.9 | -0.8 | -17.3 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.8 | 14.5 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 75.6 | 73.1 | ||
| Depreciation & Amortization | 22.8 | 20.4 | 13.2 | 13.6 | 17.3 | 17.1 | 14.8 | 15.4 | 15.0 | 14.7 | ||
| Total Operating Expenses | 163.7 | 178.8 | 153.0 | 135.6 | 134.7 | 108.4 | 153.0 | 151.4 | 92.4 | 87.6 | ||
| Operating Income | 77.2 | 43.6 | 88.0 | 102.1 | 113.9 | 133.7 | 102.7 | 100.4 | 137.5 | 112.4 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 20.3 | 0.0 | 36.8 | 19.6 | 2.6 | 0.0 | 0.2 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.3 | 0.3 | |
| Interest Expense | 19.7 | 19.7 | 19.7 | 20.0 | 7.2 | 7.8 | 9.5 | 13.6 | 17.4 | 18.4 | 26.6 | 38.7 | 42.3 | 42.9 | 42.0 | 37.7 | |
| Other Expense | 3.0 | 3.0 | -26.0 | 46.3 | 40.2 | 1.1 | -7.3 | -3.4 | 2.5 | 6.2 | 4.7 | -15.6 | 0.5 | 3.6 | 34.6 | 1.4 | |
| IBT | 313.8 | 313.8 | 431.0 | 410.9 | 26.7 | -75.0 | -11.5 | 28.6 | 49.5 | 39.6 | 28.3 | -11.8 | -2.4 | -60.5 | -42.6 | -53.2 | |
| Income Tax Expense | 80.2 | 80.2 | 118.5 | 84.3 | -1.3 | -3.8 | 2.0 | -3.0 | 9.0 | -83.7 | 1.5 | 3.0 | 1.2 | 1.0 | -0.6 | 84.1 | |
| Net Income | 233.6 | 233.6 | 312.4 | 326.7 | 28.1 | -71.3 | -13.5 | 31.7 | 40.5 | 123.4 | 26.8 | -14.7 | -3.6 | -61.6 | -42.0 | -137.3 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.0 | 3.6 | 7.2 | 9.5 | 9.6 | 9.8 | 8.9 | 8.5 | 7.5 | 4.5 | ||
| Interest Expense | 5.1 | 5.0 | 4.9 | 4.8 | 5.0 | 4.9 | 4.9 | 4.9 | 5.0 | 5.1 | ||
| Other Expense | -6.8 | -1.2 | 16.6 | -5.5 | -114.7 | 42.4 | -18.4 | 70.9 | 0.9 | 47.6 | ||
| IBT | 70.4 | 42.4 | 104.5 | 96.5 | -0.8 | 176.1 | 84.4 | 171.3 | 138.4 | 160.0 | ||
| Income Tax Expense | 16.3 | 14.6 | 25.8 | 23.6 | 11.0 | 45.0 | 22.3 | 40.2 | 35.0 | 28.0 | ||
| Net Income | 54.1 | 27.8 | 78.8 | 72.9 | -11.8 | 131.1 | 62.1 | 131.1 | 103.4 | 132.0 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $4.79 | $0.41 | $-1.06 | $-0.25 | $0.81 | $1.06 | $3.31 | $0.84 | $-0.60 | $-0.20 | $-3.40 | $-2.32 | $-7.61 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $4.65 | $0.40 | $-1.06 | $-0.25 | $0.79 | $1.03 | $3.17 | $0.82 | $-0.60 | $-0.20 | $-3.34 | $-2.32 | $-7.61 | |
| Shares Outstanding | 65.6 | 67.5 | 69.2 | 68.3 | 68.5 | 67.5 | 54.1 | 39.0 | 38.2 | 37.3 | 32.0 | 24.4 | 18.1 | 18.1 | 18.1 | 18.0 | |
| Diluted Shares Outstanding | 66.3 | 68.4 | 71.7 | 70.2 | 70.7 | 67.5 | 54.1 | 40.1 | 39.5 | 38.9 | 32.7 | 24.4 | 18.1 | 18.4 | 18.1 | 18.0 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.51 | $1.93 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.47 | $1.88 | ||
| Shares Outstanding | 65.6 | 67.2 | 68.5 | 68.7 | 69.2 | 69.5 | 69.4 | 68.8 | 68.5 | 68.4 | ||
| Diluted Shares Outstanding | 66.3 | 67.7 | 70.3 | 71.5 | 69.2 | 73.1 | 70.6 | 70.1 | 70.1 | 70.0 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 757.0 | 912.8 | 713.7 | 415.7 | 98.5 | 79.6 | 92.9 | 113.4 | 76.3 | 51.2 | 28.6 | 19.7 | 18.6 | 33.3 | |
| Short Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Cash & ST Investments | 757.0 | 912.8 | 713.7 | 415.7 | 98.5 | 79.6 | 92.9 | 113.4 | 76.3 | 51.2 | 28.6 | 19.7 | 18.6 | 33.3 | |
| Accounts Receivable | 372.3 | 321.3 | 284.3 | 213.4 | 89.3 | 54.0 | 43.5 | 43.8 | 40.3 | 36.8 | 37.3 | 41.8 | 39.2 | 42.1 | |
| Inventory | 70.5 | 68.0 | 64.0 | 35.5 | 35.1 | 35.7 | 29.2 | 33.0 | 26.1 | 17.6 | 15.6 | 15.6 | 18.3 | 18.0 | |
| Other Current Assets | 31.3 | 24.5 | 23.8 | 13.1 | 12.8 | 9.6 | 7.3 | 5.2 | 5.2 | 5.2 | 3.9 | 3.9 | 3.1 | 2.9 | |
| Total Current Assets | 1,231.1 | 1,326.6 | 1,085.8 | 677.6 | 235.8 | 184.2 | 172.9 | 195.4 | 147.9 | 110.8 | 90.1 | 81.2 | 79.2 | 96.5 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 382.0 | 695.6 | 938.5 | 912.8 | 866.4 | 757.0 | 718.3 | 713.7 | 614.1 | 414.1 | |
| Short Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Cash & ST Investments | 382.0 | 695.6 | 938.5 | 912.8 | 866.4 | 757.0 | 718.3 | 713.7 | 614.1 | 414.1 | |
| Accounts Receivable | 383.3 | 336.6 | 348.7 | 321.3 | 329.3 | 372.3 | 337.4 | 284.3 | 259.2 | 256.3 | |
| Inventory | 62.0 | 62.2 | 69.1 | 68.0 | 70.8 | 70.5 | 69.8 | 64.0 | 56.5 | 51.8 | |
| Other Current Assets | 97.8 | 107.5 | 67.4 | 24.5 | 29.2 | 31.3 | 23.4 | 23.8 | 18.6 | 30.1 | |
| Total Current Assets | 925.1 | 1,201.8 | 1,423.8 | 1,326.6 | 1,295.7 | 1,231.1 | 1,148.8 | 1,085.8 | 948.4 | 752.2 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 200.7 | 212.9 | 192.0 | 122.2 | 116.8 | 120.2 | 116.5 | 107.9 | 93.0 | 94.2 | 86.5 | 96.0 | 97.7 | 109.6 | |
| Goodwill | 61.2 | 61.2 | 61.2 | 61.2 | 61.2 | 58.6 | 15.7 | 15.7 | 15.7 | 15.7 | 15.7 | 15.7 | 15.7 | 15.7 | |
| Intangible Assets | 172.2 | 161.8 | 152.0 | 315.3 | 348.5 | 376.0 | 7.3 | 9.1 | 11.8 | 15.1 | 29.6 | 29.6 | 36.5 | 69.0 | |
| Long-Term Investments | 118.1 | 39.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.3 | 9.6 | 0.0 | |
| Other Long-Term Assets | 5.3 | 8.2 | 9.9 | 34.4 | 38.8 | 60.6 | 21.6 | 30.2 | 28.5 | 20.1 | 20.4 | 19.3 | 22.6 | 33.8 | |
| Total Long-Term Assets | 708.7 | 653.7 | 565.3 | 643.6 | 628.0 | 685.6 | 233.0 | 244.4 | 236.0 | 145.1 | 152.3 | 168.3 | 182.1 | 228.1 | |
| Total Assets | 1,939.8 | 1,980.3 | 1,651.1 | 1,321.3 | 863.8 | 869.8 | 405.9 | 439.8 | 383.9 | 255.9 | 242.4 | 249.6 | 261.3 | 324.7 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 164.1 | 157.7 | 180.8 | 212.9 | 208.9 | 158.2 | 150.1 | 192.0 | 140.3 | 130.0 | |
| Goodwill | 240.3 | 176.9 | 61.2 | 61.2 | 61.2 | 61.2 | 61.2 | 61.2 | 61.2 | 61.2 | |
| Intangible Assets | 739.3 | 359.9 | 153.7 | 161.8 | 173.6 | 172.2 | 142.1 | 152.0 | 163.3 | 221.0 | |
| Long-Term Investments | 48.2 | 45.1 | 30.4 | 39.5 | 158.8 | 116.4 | 139.0 | 1.6 | 1.6 | 1.6 | |
| Other Long-Term Assets | 52.0 | 36.4 | 36.5 | 8.2 | 6.8 | 49.5 | 51.3 | 8.3 | 54.6 | 37.5 | |
| Total Long-Term Assets | 1,351.3 | 914.3 | 631.4 | 653.7 | 753.9 | 708.7 | 682.5 | 565.3 | 573.2 | 585.5 | |
| Total Assets | 2,276.4 | 2,116.1 | 2,055.2 | 1,980.3 | 2,049.6 | 1,939.8 | 1,831.3 | 1,651.1 | 1,521.6 | 1,337.7 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 49.8 | 34.6 | 41.2 | 20.6 | 20.8 | 16.3 | 18.6 | 18.0 | 17.5 | 18.9 | 11.7 | 15.7 | 18.1 | 18.9 | |
| Short-Term Debt | 3.0 | 1.0 | 0.8 | 0.4 | 11.6 | 20.7 | 10.1 | 2.8 | 2.8 | 3.7 | 3.7 | 8.0 | 8.0 | 29.2 | |
| Other Current Liabilities | 210.5 | 205.0 | 145.3 | 226.8 | 5.4 | 1.8 | 2.1 | 2.0 | 2.8 | 1.9 | 1.7 | 24.7 | 25.5 | 0.7 | |
| Current Liabilities | 263.3 | 240.5 | 187.4 | 247.7 | 90.5 | 80.5 | 66.1 | 52.8 | 46.8 | 43.8 | 35.7 | 48.5 | 55.6 | 56.1 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 66.3 | 40.9 | 44.9 | 34.6 | 44.9 | 49.8 | 37.5 | 41.2 | 37.1 | 38.9 | |
| Short-Term Debt | 0.9 | 0.8 | 0.7 | 1.0 | 564.7 | 0.9 | 0.7 | 0.8 | 0.7 | 2.0 | |
| Other Current Liabilities | 279.7 | 237.0 | 187.1 | 205.0 | 174.5 | 212.6 | 198.9 | 145.3 | 138.8 | 113.2 | |
| Current Liabilities | 346.8 | 280.1 | 248.0 | 240.5 | 784.1 | 263.3 | 237.2 | 187.4 | 176.6 | 154.0 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 562.8 | 618.5 | 616.1 | 557.7 | 163.1 | 197.7 | 183.9 | 263.7 | 265.4 | 274.5 | 349.9 | 399.3 | 399.0 | 398.8 | |
| Capital Leases | 54.5 | 53.2 | 54.5 | 25.4 | 16.5 | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | |
| Total Liabilities | 913.1 | 892.3 | 835.3 | 874.1 | 399.3 | 355.6 | 291.3 | 368.8 | 360.6 | 362.4 | 427.7 | 488.8 | 496.8 | 497.8 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 618.6 | 614.7 | 613.7 | 618.5 | 54.5 | 617.3 | 616.6 | 616.1 | 615.0 | 590.5 | |
| Capital Leases | 0.0 | 47.9 | 47.6 | 53.2 | 53.9 | 54.1 | 54.1 | 54.5 | 54.4 | 31.3 | |
| Def. Tax Liability | 55.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 1,157.2 | 949.3 | 891.0 | 892.3 | 869.9 | 913.1 | 885.8 | 835.3 | 822.9 | 785.1 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.1 | 0.1 | 0.1 | |
| Retained Earnings | 326.6 | 445.9 | 133.5 | -193.2 | -221.2 | -149.9 | -136.5 | -168.1 | -209.0 | -332.4 | -359.2 | -344.4 | -340.9 | -279.3 | |
| Comprehensive Income | -1.2 | -1.6 | -1.0 | -1.3 | -0.5 | -2.0 | -1.0 | -1.1 | -1.0 | -0.9 | -2.0 | -1.6 | -0.4 | 1.3 | |
| Total Common Equity | 1,026.7 | 1,088.0 | 815.9 | 447.1 | 464.4 | 514.2 | 114.6 | 71.0 | 23.3 | -106.5 | -185.3 | -239.3 | -235.5 | -173.1 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Retained Earnings | 625.4 | 597.6 | 518.9 | 445.9 | 457.7 | 326.6 | 264.6 | 133.5 | 30.1 | -101.8 | |
| Comprehensive Income | -1.7 | -1.5 | -1.8 | -1.6 | -1.2 | -1.2 | -1.2 | -1.0 | -1.0 | -1.0 | |
| Total Common Equity | 1,119.2 | 1,166.8 | 1,164.2 | 1,088.0 | 1,179.7 | 1,026.7 | 945.5 | 815.9 | 698.8 | 552.6 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 620.3 | 619.4 | 616.9 | 558.1 | 174.8 | 218.4 | 194.1 | 266.5 | 268.1 | 278.1 | 353.5 | 407.3 | 407.0 | 398.8 | |
| Book Value | 1,026.7 | 1,088.0 | 815.9 | 447.1 | 464.4 | 514.2 | 114.6 | 71.0 | 23.3 | -106.5 | -185.3 | -239.3 | -235.5 | -173.1 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 1,119.2 | 1,166.8 | 1,164.2 | 1,088.0 | 1,179.7 | 1,026.7 | 945.5 | 815.9 | 698.8 | 552.6 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 428.5 | 233.6 | 312.4 | 326.7 | 28.1 | -71.3 | -13.5 | 31.7 | 40.5 | 123.4 | 26.8 | -14.7 | -3.6 | -61.6 | -42.0 | -137.3 | |
| Depreciation & Amortization | 59.9 | 70.1 | 64.6 | 60.0 | 47.9 | 42.3 | 24.7 | 13.4 | 13.9 | 19.2 | 18.3 | 19.7 | 18.3 | 25.2 | 27.4 | 32.8 | |
| Stock-Based Compensation | 62.0 | 0.0 | 76.4 | 50.5 | 29.3 | 15.9 | 14.1 | 12.5 | 8.7 | 5.9 | 2.5 | 2.0 | 1.0 | 0.6 | 1.2 | -1.0 | |
| Change Working Capital | -75.4 | -44.2 | 2.0 | -171.2 | -75.1 | -15.2 | -22.4 | 9.0 | -14.0 | -8.3 | 2.1 | -8.2 | -11.8 | -11.5 | -4.8 | -14.0 | |
| Change In Accounts Receivable | -117.6 | -17.9 | -37.7 | -68.6 | -128.5 | -33.1 | -7.5 | 0.2 | -4.0 | -3.4 | -1.1 | 0.0 | -3.6 | 2.6 | -1.4 | 9.5 | |
| Change In Accounts Payable | 9.9 | -2.5 | -8.8 | 17.2 | 0.3 | 5.4 | -4.2 | 3.2 | -2.9 | 0.6 | 5.7 | -1.7 | -4.0 | -1.1 | -2.2 | -0.9 | |
| Change In Inventories | -24.9 | -9.4 | -2.7 | -36.2 | -7.5 | -3.5 | -8.5 | 2.0 | -8.7 | -9.6 | -3.6 | -2.6 | 1.5 | -4.7 | -6.9 | -22.3 | |
| Other Non-cash Items | 123.4 | 109.1 | 114.0 | 94.1 | 302.5 | 78.5 | 14.2 | 6.6 | 5.9 | 7.1 | -0.4 | 22.2 | 7.6 | 32.4 | 17.4 | 60.9 | |
| Cash from Operations | 441.0 | 0.0 | 0.0 | 305.3 | 281.8 | 53.9 | 16.4 | 80.4 | 61.2 | 54.8 | 49.6 | 21.8 | 11.6 | -15.6 | -0.4 | 23.2 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 54.1 | 27.8 | 78.8 | 72.9 | -11.8 | 131.1 | 62.1 | 131.1 | 103.4 | 132.0 | |
| Depreciation & Amortization | 22.8 | 20.4 | 13.2 | 13.6 | 17.3 | 17.1 | 14.8 | 15.4 | 15.0 | 14.7 | |
| Stock-Based Compensation | 0.0 | 0.0 | 22.3 | 21.2 | 0.0 | 0.0 | 0.0 | 15.4 | 14.2 | 14.0 | |
| Change Working Capital | -16.3 | 1.3 | -10.9 | -18.3 | 33.0 | 38.6 | -56.7 | -12.9 | -27.6 | 21.8 | |
| Change In Accounts Receivable | -2.1 | 12.8 | -2.3 | -26.4 | 7.2 | 43.1 | -32.6 | -55.4 | -25.6 | -4.0 | |
| Change In Accounts Payable | -32.0 | 20.1 | 4.4 | 5.0 | -10.0 | -5.7 | 10.3 | -3.5 | 5.0 | -2.0 | |
| Change In Inventories | -3.0 | -0.9 | -5.7 | 0.3 | 4.4 | 0.9 | 0.5 | -8.5 | -10.2 | -6.7 | |
| Other Non-cash Items | 31.3 | 26.9 | -8.7 | 16.1 | 142.5 | -15.0 | 83.4 | -33.4 | 5.7 | -47.8 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 112.3 | 116.7 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -46.1 | -41.5 | -79.6 | -46.6 | -18.3 | -12.1 | -12.5 | -22.1 | -20.1 | -17.5 | -7.4 | -13.2 | -8.1 | -5.0 | -7.9 | -7.7 | |
| Acquisitions | -16.6 | -575.7 | -80.9 | 0.0 | 0.0 | 0.0 | 17.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | -78.3 | -10.0 | -83.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Sales of Investment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | 26.6 | 0.0 | 0.0 | 52.5 | -258.2 | 15.8 | -10.0 | 0.0 | 1.0 | 1.2 | 10.7 | 0.0 | 0.5 | 1.5 | -0.2 | 0.0 | |
| Cash from Investing | -80.5 | 0.0 | 0.0 | 5.9 | -276.5 | 3.7 | -4.9 | -22.1 | -19.1 | -16.3 | 3.3 | -13.2 | -7.7 | -3.5 | -8.1 | -7.7 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -14.2 | -10.6 | -13.4 | -8.7 | -16.4 | -15.8 | -11.2 | -8.3 | -12.1 | -14.6 | |
| Acquisitions | 2.3 | -308.8 | -219.1 | -55.0 | -8.0 | -47.0 | -33.9 | -106.3 | 45.3 | 0.0 | |
| Investments | -5.0 | 0.0 | 0.0 | 0.0 | 0.0 | -5.0 | 0.0 | -78.3 | 0.0 | 0.0 | |
| Sales of Investment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -45.3 | 97.8 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -12.1 | 83.2 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -0.8 | 0.0 | 0.0 | -0.7 | -175.4 | -43.3 | -15.5 | -275.4 | -2.9 | -286.7 | -78.7 | -419.7 | -5.6 | -1.3 | -1.5 | -10.0 | |
| Debt Issued | 30.2 | 619.4 | 2.5 | 59.6 | 558.7 | -0.3 | 39.8 | 203.0 | 1.2 | 276.7 | 3.3 | 365.9 | 5.8 | 9.5 | 400.4 | 10.0 | |
| Issuance of Common Stock | 4.7 | 0.0 | 0.0 | 1.9 | 1.4 | 0.8 | 0.7 | 0.6 | 0.4 | 0.2 | 50.9 | 73.5 | 0.0 | 0.4 | 0.6 | 162.3 | |
| Repurchase of Common Stock | -22.2 | -300.0 | -100.0 | 0.0 | -75.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -0.2 | -44.1 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -3.5 | -101.1 | |
| Other Financing Activities | -19.9 | 0.0 | 0.0 | -14.3 | 560.7 | 3.2 | -7.1 | 195.9 | -2.2 | 273.1 | -2.4 | 347.1 | 3.3 | 6.8 | -0.4 | -9.2 | |
| Cash from Financing | -17.1 | 0.0 | 0.0 | -13.1 | 311.7 | -39.3 | -21.9 | -78.9 | -4.7 | -13.5 | -30.2 | 1.0 | -2.3 | 5.6 | -5.1 | -2.2 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.2 | |
| Debt Issued | 619.4 | 3.9 | 1.1 | -5.0 | 0.2 | 1.1 | 0.9 | 0.4 | 1.3 | 25.0 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 1.0 | |
| Repurchase of Common Stock | -100.0 | -100.0 | -100.0 | 0.0 | -100.0 | 0.0 | 0.0 | 0.0 | -0.8 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.8 | -0.7 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.5 | 0.1 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 343.0 | -553.7 | 199.2 | 298.0 | 316.6 | 18.0 | -10.2 | -20.5 | 37.1 | 25.1 | 22.6 | 8.9 | 1.2 | -14.7 | -13.0 | 13.2 | |
| Closing Cash Balance | 757.0 | 360.8 | 914.5 | 715.3 | 417.2 | 100.7 | 82.7 | 92.9 | 113.4 | 76.3 | 51.2 | 28.6 | 19.7 | 18.6 | 33.3 | 46.3 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -22.9 | -313.6 | -243.0 | 25.7 | 46.4 | 109.4 | 38.7 | 4.6 | 99.5 | 200.1 | |
| Closing Cash Balance | 360.8 | 382.0 | 697.3 | 940.2 | 912.8 | 866.4 | 757.0 | 719.9 | 715.3 | 615.7 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 394.8 | 354.1 | 493.1 | 258.7 | 263.4 | 41.8 | 3.9 | 58.3 | 41.1 | 37.2 | 42.2 | 8.6 | 3.5 | -20.6 | -8.3 | 15.5 | |
| Real Free Cash Flow | 332.8 | 354.1 | 416.7 | 208.2 | 234.2 | 25.8 | -10.2 | 45.8 | 32.3 | 31.3 | 39.7 | 6.6 | 2.4 | -21.2 | -9.5 | 16.5 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 81.4 | 94.7 | 73.7 | 98.8 | 139.0 | 159.3 | 73.5 | 119.0 | 100.2 | 102.1 | |
| Real Free Cash Flow | 81.4 | 94.7 | 51.4 | 77.6 | 139.0 | 159.3 | 73.5 | 103.6 | 86.0 | 88.1 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 21.7 | 63.1 | 2356.8 |
| P/S | 3.3 | 3.1 | 70.5 |
| P/B | 4.5 | 5.2 | 2015.4 |
| P/FCF | 16.6 | 66.5 | 7573.5 |
| Market cap | $3.5 | $4.5 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 27.2 % | 66.5 % | 0 % |
| Debt to Income | 265.2 % | 325.1 % | 0 % |
| Debt to Free cash flow | 203 % | 902.6 % | 0 % |
| Interest expense percentage | 6.4 % | -50.8 % | 26.2 % |
| Current ratio | 2.7 | 2.8 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 20.9 % | 36.3 % | 0 % |
| ROA | 10.3 % | 5.7 % | 0 % |
| CapEx to Revenue | 3.2 % | 3.4 % | 6 % |
| RaD to Revenue | 0 % | 9 % | 0 % |
| ROEM | 1,907,931.9 | 580174.6 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 62.2 % | 48.2 % | 74.8 % |
| Operating margin | 22.8 % | 11.6 % | 35 % |
| Net margin | 11 % | 5.6 % | 34.1 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | -1.4 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 67.7 mil | 47.7 mil |
| Employee count | 0.8 tis | 0.6 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
